{"entity":{"id":"nct07483983","kind":"trial","name":"Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Bi","aka":["UNLOCK ASP3082"],"tldr":"A phase 2 trial of setidegrasib in pancreatic cancer, run by Gustave Roussy, Cancer Campus, Grand Paris, now recruiting.","summary":"Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance is a phase 2, interventional study registered as NCT07483983 by Gustave Roussy, Cancer Campus, Grand Paris, with a registry enrolment figure of 60 participants, started 2026-03-25 and due to reach its primary completion in 2027-09. Interventions recorded: ASP3082. Conditions listed: Metastatic/Locally Advanced Non-Small-Cell Lung Cancer; Metastatic/Locally Pancreatic Ductal Adenocarcinoma. Primary outcome: Evaluate the best overall response (BOR) based on investigator assessment per RECIST v1.1. Sites: France. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07483983","url":"https://clinicaltrials.gov/study/NCT07483983"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":["kras-inhibitors"],"targets":[],"drugs":["setidegrasib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07483983","phase":"2","setting":"Phase 2, Multicenter, Open Label, Platform Study Investigating ASP3082 in Patients With Metastaic/Locally Non-Small-Cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07483983/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"}],"drug":[{"id":"setidegrasib","kind":"drug","name":"Setidegrasib","route":"/drugs/setidegrasib/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}